Daily News Analysis

Coartem Baby

stylish_lining

The approval of Coartem Baby by Swiss authorities is a significant milestone in the fight against malaria, particularly for one of the most vulnerable populations with babies and very young children.

About Coartem Baby

Coartem Baby is a specially formulated drug designed to treat malaria in infants who weigh between 2-5 kg, roughly covering newborns up to 6 months old. This is a major breakthrough because, until now, infants with malaria had to use adult or older child formulations, which increased the risk of overdose or improper dosing.

Key Features of Coartem Baby:

  • Active Ingredients: It contains artemether and lumefantrine, which work together to combat the malaria parasite. These two drugs are widely used in malaria treatment for older children and adults but have now been specially tailored for infants.

  • Formulation: The formulation is designed to dissolve easily, even when mixed with breast milk, making it easier to administer. Additionally, it has a sweet cherry flavour to encourage better acceptance by infants.

  • Safety & Accuracy: By providing a dosage specifically for infants, the risk of overdose is minimized. This is crucial, as malaria treatment can often be complicated for the youngest children due to their smaller size and different metabolic rates.

Development and Collaborative Effort:

  • Developed by Novartis in partnership with Medicines for Malaria Venture (MMV) and supported by international governments and organizations such as the UK, Switzerland, Netherlands, the World Bank, and the Rockefeller Foundation.

  • Clinical Trials: The drug underwent assessments and clinical trials in eight African countries—Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda—which are some of the most malaria-endemic areas in the world.

Why This Is a Game-Changer for Malaria Treatment

  1. Targeting a Vulnerable Group: Infants are among the most vulnerable to malaria. The disease can be fatal for babies, especially in regions where healthcare access is limited. Coartem Baby’s approval is a huge step toward providing life-saving treatment for this group.

  2. Reducing Overdose Risk: Prior to Coartem Baby, infants had to rely on formulations meant for older children or adults. This often led to inappropriate dosing, increasing the risk of side effects or overdose. Coartem Baby eliminates this risk with its carefully adjusted formulation.

  3. Ease of Administration: The fact that the drug dissolves easily in breast milk, combined with its sweet flavour, will make it much easier for caregivers to administer the medicine, improving adherence and treatment outcomes.

About Malaria

Malaria remains one of the most deadly infectious diseases, particularly in tropical and subtropical regions. While significant progress has been made in reducing malaria rates, the disease still poses a serious health threat, especially for young children under five, pregnant women, and people living in malaria-endemic areas.

Key Facts About Malaria:

  • Transmission: Malaria is caused by Plasmodium parasites transmitted through the bite of an infected female Anopheles mosquito.

  • Not Contagious: Malaria is not contagious from person to person but can be spread through infected blood or contaminated needles.

  • Most Dangerous Species: The two most dangerous malaria-causing species are Plasmodium falciparum and Plasmodium vivax.

Symptoms & Risks:

  • Early Symptoms: Fever, chills, and headaches usually appear 10–15 days after infection.

  • Severe Symptoms: Without treatment, severe malaria can lead to complications such as seizures, difficulty breathing, jaundice, dark urine, and death.

  • Partial Immunity: People living in endemic regions can develop partial immunity over time, which can make the diagnosis difficult since their symptoms may be less severe.

Conclusion

The approval of Coartem Baby is a significant leap forward in malaria treatment, addressing a critical gap in the healthcare options available for infants. By making the treatment safer and more effective for babies, this drug has the potential to save countless lives and contribute to the global effort to eliminate malaria.


 

Critical Minerals

India’s first auction of deep-sea blocks for the extraction of critical minerals has been delayed indefinitely after receiving a poor response from bidders. This auction was expected to be a
Share It

President's Rule

The extension of President’s Rule in Manipur has brought to the fore the historical and controversial use of Article 356 of the Indian Constitution, shedding light on how its imposition disr
Share It

Beggars' Homes in India

In M.S. Patter v. State of NCT of Delhi, the Supreme Court (SC) held that state-run beggars’ homes are not merely penal institutions or charitable endeavors but are instead constitutional tr
Share It

Public Distribution System (PDS)

India's Public Distribution System (PDS) has long been a cornerstone of food security, ensuring access to subsidised cereals for millions of people. However, a recent Crisil study using the &l
Share It

Saudi-Pakistan Strategic Mutual Defense Agreement (SMDA)

The recent Saudi-Pakistan Strategic Mutual Defense Agreement (SMDA) represents a major shift in the geopolitical landscape of the Middle East and South Asia, with significant implications for Indi
Share It

Wassenaar Arrangement

The Wassenaar Arrangement is facing significant challenges in adapting its controls to the rapid growth of cloud technology. This issue highlights the need to update its control lists and enforcem
Share It

National Crime Records Bureau (NCRB)

The National Crime Records Bureau (NCRB) report for 2023 highlights a 9.2% increase in crimes against children in India, with 177,335 cases registered in total. This reflects a concerning rise in
Share It

Doctrine of Contributory Negligence

The Andhra Pradesh High Court recently made an important ruling regarding the doctrine of contributory negligence in criminal law. The court clarified that contributory negligence does not apply t
Share It

Perpetual Bonds

The Indian Renewable Energy Development Agency Ltd (IREDA) recently raised ₹453 crore at an interest rate of 7.70% per annum through its second issue of Perpetual Bonds. This move is part of the
Share It

Fake News

The Standing Committee on Communications and Information Technology in India has recently proposed several measures aimed at tackling the pervasive issue of fake news and misinformation, acknowled
Share It

Newsletter Subscription


ACQ IAS
ACQ IAS